Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Public ClinicalTrials.gov record NCT04815720. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1b/2 Study of the Combination of Pepinemab and Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of the study is to evaluate the safety and tolerability of pepinemab in combination with pembrolizumab as first-line treatment and determine a recommended Phase 2 dose (RP2D) in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).
Study identification
- NCT ID
- NCT04815720
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 49 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years to 100 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 9, 2021 (Actual)
- Primary completion
- Jul 24, 2024 (Actual)
- Completion
- Jul 24, 2024 (Actual)
- Last update posted
- Jan 8, 2025
2021 – 2024
United States locations
- U.S. sites
- 15
- U.S. states
- 12
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Highlands Oncology Group, PA - North Hills | Springdale | Arkansas | 72762 | — |
| California Cancer Associates for Research and Excellence (CCARE)-Fresno | Fresno | California | 93720 | — |
| UCSF Medical Center at Mission Bay | San Francisco | California | 94158 | — |
| Yale Cancer Center | New Haven | Connecticut | 06510 | — |
| AdventHealth Celebration | Celebration | Florida | 34747 | — |
| AdventHealth Orlando | Orlando | Florida | 32803 | — |
| Emory Saint Joseph's Hospital | Atlanta | Georgia | 30308 | — |
| American Oncology Partners of Maryland, PA | Bethesda | Maryland | 20817 | — |
| Siteman Cancer Center - Washington University Medical Campus | St Louis | Missouri | 63110 | — |
| Northwell Health - Centers for Advanced Medicine | Lake Success | New York | 11042 | — |
| University of Rochester | Rochester | New York | 14642 | — |
| Messino Cancer Centers | Asheville | North Carolina | 28806 | — |
| Gabrail Cancer Research Center | Canton | Ohio | 44718 | — |
| Allegheny General Hospital | Pittsburgh | Pennsylvania | 15212 | — |
| Virginia Cancer Specialists - Fairfax | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04815720, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 8, 2025 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04815720 live on ClinicalTrials.gov.